Research News and Research

RSS

Erbitux recognized as one of the major clinical cancer advances of 2009

The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

16 Nov 2009

Color of skin impacts health, say researchers

Researchers from the universities of Bristol and St. Andrews in the UK have found that the color of a person's skin affects how healthy and therefore attractive they appear, and have found that diet may be crucial to achieving the most desirable complexion. The work will be published in the December issue of Springer's International Journal of Primatology.

16 Nov 2009

Fate Therapeutics announces the completion of $30 million Series B financing

Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.

16 Nov 2009

HIRC recognizes CDPHP for offering best disease management program in upstate New York

Health Dialog Services Corporation, a leading provider of healthcare decision programs, today announced that its client, Capital District Physicians’ Health Plan, Inc. (CDPHP®), has been recognized by the Health Industries Research Cos. (HIRC) for offering the best disease management program in upstate New York.

16 Nov 2009

Advanced Cell Technology to raise funds through private placements

Advanced Cell Technology, Inc., announced today that it has entered into definitive agreements on three private placements with institutional and other accredited investors under which the Company has received definitive commitments in excess of $15 million.

16 Nov 2009

CCSA to focus on role of treatment systems at Canada's Issues of Substance 2009 conference

The Canadian Centre on Substance Abuse (CCSA) today announced that it will open Issues of Substance (IOS) 2009, Canada's biennial conference on substance abuse, with a focus on the role of treatment systems. More than 13 sessions will examine the role of treatment from a variety of perspectives, including the Models of Care project in the UK, the National Treatment Strategy in Canada (NTS) and case study and research presentations reviewing the effectiveness of a variety of integrated programs in Canada.

16 Nov 2009

Platelet function tests predict heart attacks in patients pre-treated with two anti-clotting medications before coronary stenting

Three platelet function tests all identified heart patients who will have blood cells that remain sticky, increasing heart attack risk, despite being pre-treated with two anti-clotting medications before coronary stenting, researchers reported at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

Myeloma UK launches innovative clinical trial network

Yorkshire myeloma patients are set to be among the first to benefit from an innovative Myeloma Clinical Trial Network launched by Myeloma UK.

16 Nov 2009

Alcohol mixed with energy drinks: Higher prevalence of sexual assault and injury in college students

Emergency physician Mary Claire O'Brien, M.D., of Wake Forest University Baptist Medical Center, has done extensive research on the risks and dangers of alcoholic energy drinks (AEDs).

16 Nov 2009

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

Human Genome Sciences, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) relating to the Company’s Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational anthrax. The FDA issues Complete Response Letters to request additional information needed to complete the review of a BLA.

16 Nov 2009

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported its financial results for the quarter ended September 30, 2009.

16 Nov 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta Incorporated today announced financial results for the quarter and nine months ended September 30, 2009. The Company also announced a restructuring, reduction in workforce, and re-ordering of clinical development priorities.

16 Nov 2009

Yongye International revenues increases 60.9% year-over-year in third quarter 2009

Yongye International, Inc. a leading manufacturer, developer and distributor of Shengmingsu brand plant and animal nutrient products in the People's Republic of China (PRC), today reported its financial results for the quarter ended September 30, 2009.

16 Nov 2009

Genta announces Phase 3 trial results of Genasense

Genta Incorporated today announced preliminary results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine (DTIC) administered with or without Genasense® in patients who have not previously received chemotherapy.

16 Nov 2009

Publicly available research center for H1N1 influenza pandemic launched

ebrary®, a leading provider of digital content products and technologies, today announced that it has created a publicly available research center featuring a highly interactive, searchable database of documents pertaining to the H1N1 influenza pandemic.

16 Nov 2009

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced financial results for the third quarter, ended September 30, 2009.

16 Nov 2009

SANUWAVE Health reports financial results for the three months ended September 30, 2009

SANUWAVE Health, Inc.,, an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reports its achievements and financial results for the three and nine months ended September 30, 2009.

16 Nov 2009

Flamel Technologies total revenues up $9.9 million in the third quarter 2009

Flamel Technologies today announced its financial results for the third quarter of 2009.

16 Nov 2009

EntreMed announces financial results for the third quarter of 2009

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three- and nine-month periods ending September 30, 2009.

16 Nov 2009

Indefinite expansion of adult cells without recourse to stem cell intermediates possible

Is the indefinite expansion of adult cells possible without recourse to stem cell intermediates? The team led by Michael Sieweke at the Centre d'immunologie de Marseille Luminy (Université Aix-Marseille 2 / CNRS / INSERM) has proved that this is the case by achieving the ex vivo regeneration for several months of macrophages, specialized cells in the immune system.

16 Nov 2009

Research News and Research

Erbitux recognized as one of the major clinical cancer advances of 2009

Color of skin impacts health, say researchers

Fate Therapeutics announces the completion of $30 million Series B financing

HIRC recognizes CDPHP for offering best disease management program in upstate New York

Advanced Cell Technology to raise funds through private placements

CCSA to focus on role of treatment systems at Canada's Issues of Substance 2009 conference

Platelet function tests predict heart attacks in patients pre-treated with two anti-clotting medications before coronary stenting

Myeloma UK launches innovative clinical trial network

Alcohol mixed with energy drinks: Higher prevalence of sexual assault and injury in college students

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Yongye International revenues increases 60.9% year-over-year in third quarter 2009

Genta announces Phase 3 trial results of Genasense

Publicly available research center for H1N1 influenza pandemic launched

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

SANUWAVE Health reports financial results for the three months ended September 30, 2009

Flamel Technologies total revenues up $9.9 million in the third quarter 2009

EntreMed announces financial results for the third quarter of 2009

Indefinite expansion of adult cells without recourse to stem cell intermediates possible

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring